Animal models of sepsis: Setting the stage

被引:666
作者
Buras, JA
Holzmann, B
Sitkovsky, M
机构
[1] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA
[2] Tech Univ Munich, Dept Surg, D-81675 Munich, Germany
[3] Northeastern Univ, Dept Biol, Consortium, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA
[4] Northeastern Univ, Dept Pharmaceut Sci, Consortium, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nrd1854
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Sepsis is a state of disrupted inflammatory homeostasis that is often initiated by infection. The development and progression of sepsis is multi-factorial, and affects the cardiovascular, immunological and endocrine systems of the body. The complexity of sepsis makes the clinical study of sepsis and sepsis therapeutics difficult. Animal models have been developed in an effort to create reproducible systems for studying sepsis pathogenesis and preliminary testing of potential therapeutic agents. However, demonstrated benefit from a therapeutic agent in animal models has rarely been translated into success in human clinical trials. This review summarizes the common animal sepsis models and highlights how results of recent human clinical trials might affect their use.
引用
收藏
页码:854 / 865
页数:12
相关论文
共 107 条
[1]   SEQUENTIAL CARDIORESPIRATORY PATTERNS IN SEPTIC SHOCK [J].
ABRAHAM, E ;
SHOEMAKER, WC ;
BLAND, RD ;
COBO, JC .
CRITICAL CARE MEDICINE, 1983, 11 (10) :799-803
[2]   Recognition of pathogen-associated molecular patterns by TLR family [J].
Akira, S ;
Hemmi, H .
IMMUNOLOGY LETTERS, 2003, 85 (02) :85-95
[3]   TREATMENT WITH RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR-ALPHA PROTECTS RATS AGAINST THE LETHALITY, HYPOTENSION, AND HYPOTHERMIA OF GRAM-NEGATIVE SEPSIS [J].
ALEXANDER, HR ;
SHEPPARD, BC ;
JENSEN, JC ;
LANGSTEIN, HN ;
BURESH, CM ;
VENZON, D ;
WALKER, EC ;
FRAKER, DL ;
STOVROFF, MC ;
NORTON, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :34-39
[4]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[5]   Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin [J].
Ayala, A ;
Song, GY ;
Chung, CS ;
Redmond, KM ;
Chaudry, IH .
CRITICAL CARE MEDICINE, 2000, 28 (08) :2949-2955
[6]   Immune dysfunction in murine polymicrobial sepsis: Mediators, macrophages, lymphocytes and apoptosis [J].
Ayala, A ;
Chaudry, IH .
SHOCK, 1996, 6 :S27-S38
[7]   Differential induction of apoptosis in lymphoid tissues during sepsis: Variation in onset, frequency, and the nature of the mediators [J].
Ayala, A ;
Herdon, CD ;
Lehman, DL ;
Ayala, CA ;
Chaudry, IH .
BLOOD, 1996, 87 (10) :4261-4275
[8]   POLYMICROBIAL SEPSIS BUT NOT LOW-DOSE ENDOTOXIN INFUSION CAUSES DECREASED SPLENOCYTE IL-2/IFN-GAMMA RELEASE WHILE INCREASING IL-4/IL-10 PRODUCTION [J].
AYALA, A ;
DEOL, ZK ;
LEHMAN, DL ;
HERDON, CD ;
CHAUDRY, IH .
JOURNAL OF SURGICAL RESEARCH, 1994, 56 (06) :579-585
[9]  
BAKER CC, 1983, SURGERY, V94, P331
[10]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709